NeurologyLive® Mind Moments®

Special Episode: FDA Approves Tenecteplase for Acute Ischemic Stroke


Listen Later

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we cover the recent approval of Genentech's tenecteplase, marketed as TNKase, as a new treatment for adults with acute ischemic stroke (AIS). The thrombolytic medicine is an intravenous tissue plasminogen activator that is clot-dissolving, administered as a single 5-second intravenous bolus. Tenecteplase is only the second such approval for this indication, following the 2015 approval of alteplase (Activase; Genentech); however, tenecteplase is considered faster and more simply administered than alteplase. To better understand the implications of this approval, NeurologyLive sat down with stroke expert Bijoy Menon, MD, MSc, FRCPC, a professor of neurology at the University of Calgary. In the interview, Menon talked about the downstream impacts of having another approved therapy, how tenecteplase differs from other thrombolytic agents, and the efficacy and safety that supported its approval. Furthermore, he provided commentary on how the approval continues to chip away toward the idea of precision medicine and personalizing treatments for patients with AIS. 


For more of NeurologyLive's coverage of sodium oxybate's (Lumryz) expanded indication, head here: FDA Approves Tenecteplase for Acute Ischemic Stroke

Episode Breakdown:
  • 1:40 – Immediate reaction and significance of tenecteplase approval
  • 5:30 – Safety considerations and administration when prescribing tenecteplase
  • 10:20 – Supportive efficacy and safety, phase 3 AcT trial, and other supplementary studies
  • 14:50 – Advancing precision medicine, treatment personalization with new approval

    Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    ...more
    View all episodesView all episodes
    Download on the App Store

    NeurologyLive® Mind Moments®By NeurologyLive

    • 4.6
    • 4.6
    • 4.6
    • 4.6
    • 4.6

    4.6

    10 ratings


    More shows like NeurologyLive® Mind Moments®

    View all
    The Clark Howard Podcast by Clark Howard

    The Clark Howard Podcast

    5,380 Listeners

    Neurology® Podcast by American Academy of Neurology

    Neurology® Podcast

    285 Listeners

    NEJM This Week by NEJM Group

    NEJM This Week

    322 Listeners

    Practical Neurology Podcast by BMJ Group

    Practical Neurology Podcast

    45 Listeners

    JAMA Neurology Author Interviews by JAMA Network

    JAMA Neurology Author Interviews

    14 Listeners

    BMJ Best Practice Podcast by BMJ Group

    BMJ Best Practice Podcast

    27 Listeners

    Neurology Today in 5 by American Academy of Neurology

    Neurology Today in 5

    21 Listeners

    Neurology Minute by American Academy of Neurology

    Neurology Minute

    132 Listeners

    Dateline NBC by NBC News

    Dateline NBC

    47,856 Listeners

    The Ezra Klein Show by New York Times Opinion

    The Ezra Klein Show

    15,311 Listeners

    Chanticleer by Australian Financial Review

    Chanticleer

    20 Listeners

    Movers and Shakers: a podcast about life with Parkinson's by Podot

    Movers and Shakers: a podcast about life with Parkinson's

    98 Listeners

    The Top Line by Fierce Life Sciences

    The Top Line

    12 Listeners

    Continuum Audio by American Academy of Neurology

    Continuum Audio

    77 Listeners

    The Economics Show by Financial Times

    The Economics Show

    98 Listeners